Active substance
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| APTIOM | 200MG; 400MG; 600MG; 800MG | tablet · oral | SUMITOMO PHARMA AM | Prescription | 8 Nov 2013 |
| ESLICARBAZEPINE ACETATE | 200MG; 400MG; 600MG; 800MG | tablet · oral | DR REDDYS | Prescription | 29 Jun 2021 |
| ESLICARBAZEPINE ACETATE | 200MG; 400MG; 600MG; 800MG | tablet · oral | HETERO LABS LTD V | Prescription | 3 Aug 2023 |
| ESLICARBAZEPINE ACETATE | 200MG; 400MG; 600MG; 800MG | tablet · oral | ALKEM LABS LTD | Prescription | 6 Oct 2023 |
| ESLICARBAZEPINE ACETATE | 200MG; 400MG; 600MG; 800MG | tablet · oral | APOTEX | Prescription | 7 Dec 2023 |
| ESLICARBAZEPINE ACETATE | 200MG; 400MG; 600MG; 800MG | tablet · oral | TORRENT | Prescription | 27 Feb 2024 |
| ESLICARBAZEPINE ACETATE | 200MG; 400MG; 600MG; 800MG | tablet · oral | LUPIN | Prescription | 27 Mar 2024 |
| ESLICARBAZEPINE ACETATE | 200MG; 400MG; 600MG; 800MG | tablet · oral | JUBILANT GENERICS | Prescription | 4 Aug 2025 |
| ESLICARBAZEPINE ACETATE | 200MG; 400MG; 600MG; 800MG | tablet · oral | SPH ZHONGXI PHARM | Prescription | 3 Nov 2025 |
| ESLICARBAZEPINE ACETATE | 200MG; 400MG; 600MG; 800MG | tablet · oral | AUROBINDO PHARMA | Prescription | 5 Aug 2026 |
Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.
Exalief is indicated as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-ESLICARBAZEPINE | 02537931 | 200 MG | TABLET · ORAL | APOTEX INC |
| APO-ESLICARBAZEPINE | 02537958 | 400 MG | TABLET · ORAL | APOTEX INC |
| APO-ESLICARBAZEPINE | 02537966 | 600 MG | TABLET · ORAL | APOTEX INC |
| APO-ESLICARBAZEPINE | 02537974 | 800 MG | TABLET · ORAL | APOTEX INC |
| AURO-ESLICARBAZEPINE | 02527421 | 200 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-ESLICARBAZEPINE | 02527448 | 400 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-ESLICARBAZEPINE | 02527456 | 600 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-ESLICARBAZEPINE | 02527464 | 800 MG | TABLET · ORAL | AURO PHARMA INC |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | APTIOM 200 MG TABLET | $44.24295 | per EA | 1 Jan 2026 |
| US NADAC | APTIOM 400 MG TABLET | $44.00708 | per EA | 23 Sep 2026 |
| US NADAC | APTIOM 600 MG TABLET | $44.42614 | per EA | 23 Sep 2026 |
| US NADAC | APTIOM 800 MG TABLET | $44.16672 | per EA | 23 Sep 2026 |
| US NADAC | ESLICARBAZEPINE 200 MG TABLET | $1.67576 | per EA | 30 Sep 2026 |
| US NADAC | ESLICARBAZEPINE 400 MG TABLET | $1.85082 | per EA | 30 Sep 2026 |
| US NADAC | ESLICARBAZEPINE 600 MG TABLET | $2.32378 | per EA | 30 Sep 2026 |
| US NADAC | ESLICARBAZEPINE 800 MG TABLET | $1.72576 | per EA | 30 Sep 2026 |
| NHS Drug Tariff | Eslicarbazepine 200mg tablets | £68.00 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Eslicarbazepine 50mg/1ml oral suspension sugar free | £56.67 | 200 ml | 1 Oct 2026 |
| NHS Drug Tariff | Eslicarbazepine 800mg tablets | £25.87 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.